Drugs / CETUXIMAB SAROTALOCAN
CETUXIMAB SAROTALOCAN
also known as
ASP-1929 · ASP-1929 Photoimmunotherapy · cetuximab sarotalocan sodium · Cetuximab-irdye 700dx conjugate · Cetuximab-IRDye-700DX · RM-1929
Other / unclassified targets EGFR
Trials 8 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/23 trials | ||||||
| Phase 1/2 | NCT07698613 | Sep 2026 → Mar 2029 expected | pancreatic neoplasm | Brown University | Not yet recruiting | No outcome recorded |
| Phase 1/2 | NCT04305795 | Dec 2020 → Jun 2026 overdue | head and neck squamous cell carcinoma, skin squamous cell carcinoma | Rakuten Medical, Inc. | Active not recruiting | No outcome recorded |
| Phase 1/2 | NCT02422979 | Jun 2015 → Feb 2019 | head and neck cancer | Rakuten Medical, Inc. | Completed | No outcome recorded |
| Phase 23 trials | ||||||
| Phase 2 | NCT06943664 | Aug 2026 → May 2027 expected | non-small cell lung carcinoma | Roswell Park Cancer Institute | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT05265013 | Apr 2022 → Nov 2023 | head and neck cancer | Rakuten Medical, Inc. | Terminated | No outcome recorded |
| Phase 2 | NCT05182866 | Jan 2022 → Jul 2024 overdue | head and neck squamous cell carcinoma | Rakuten Medical, Inc. | Active not recruiting | No outcome recorded |
| Phase 32 trials | ||||||
| Phase 3 | NCT06699212 | Dec 2024 → Sep 2028 expected | head and neck squamous cell carcinoma | Rakuten Medical, Inc. | Recruiting | No outcome recorded |
| Phase 3 | NCT03769506 | May 2019 → Dec 2025 overdue | head and neck squamous cell carcinoma | Rakuten Medical, Inc. | Active not recruiting | No outcome recorded |
Evidence & citations 11 cited values
Every value below carries the sentence it was read from. 9 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CETUXIMAB SAROTALOCAN | ChEMBL registry synonym — accepted as the source's own label CHEMBL4298088 ↗ |
| Known as | ASP-1929 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04305795 ↗ |
| Known as | ASP-1929 Photoimmunotherapy | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06699212 ↗ |
| Known as | cetuximab sarotalocan sodium | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06943664 ↗ |
| Known as | Cetuximab-irdye 700dx conjugate | ChEMBL registry synonym — accepted as the source's own label CHEMBL4298088 ↗ |
| Known as | Cetuximab-IRDye-700DX | ChEMBL registry synonym — accepted as the source's own label CHEMBL4298088 ↗ |
| Known as | RM-1929 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02422979 ↗ |
| Action | Deplete | “can lead to the selective destruction of the HNSCC cancer cells” NCT02422979 ↗ |
| Modality | Other / unclassified | “ASP-1929 Photoimmunotherapy” NCT03769506 ↗ |
| Route | Intravenous | “the administration by infusion of the drug RM-1929” NCT02422979 ↗ |
| Target | EGFR | “the drug RM-1929 targeting the cancer protein EGFR” NCT02422979 ↗ |